Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Allon Therapeutics to present at International CNS Disease Congress
July 10th, 2007
Allon Therapeutics Inc. (the "Corporation") (TSX:NPC), the Neuroprotection CompanyTM, announced that the Company has been invited to present Allon's clinical progress and strategy for AL-108 at the 3rd Annual CNS Diseases Congress, June 25th to 26th, 2007, located at the Hilton Boston Back Bay Hotel, in Boston Massachusetts. The presentation by Dr. Bruce Morimoto, Allon's VP of Drug Development, is titled "Neuroprotection by AL-108, an Intranasal Peptide" and will take place on Monday June 25th at 9:30am EST. Dr. Morimoto's plenary presentation will address and illustrate the neuroprotective effect of Allon's drug, AL-108 and explain the development strategy behind the...
Source: Drug Law Weekly (2007-07-10)
|
